Zanubrutinib is an oral small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), which approval by the FDA in November 2019. It is used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who previously received therapy.